Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 05, 2023 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has...
Immuron Approved to Commence Clinical Study in C.Difficile Infection (CDI)
August 09, 2017 08:30 ET
|
Immuron Limited
Key Highlights Final approval for key first in-human Clinical Study for CDI treatment, by Israeli Ministry of HealthAn estimated 28,000 patients die each year from CDI infections in the USA...
SteraMist™ Contributes to Substantial Reduction in Clostridium Difficile Burden in Hospital
April 03, 2017 16:05 ET
|
TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., April 03, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination and infection prevention company that specializes in...
TOMI™ Takes Lead on Fight Against C. diff With “List K” Listing
March 13, 2017 08:00 ET
|
TOMI Environmental Solutions, Inc.
BEVERLY HILLS, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- TOMI™ Environmental Solutions, Inc. (TOMI) (OTCQX:TOMZ), As Clostridium Difficile Spores (C. diff) continue to plague hospitals around the...
Fecal transplant pills: Large-scale production begins
October 28, 2015 08:39 ET
|
OpenBiome
BOSTON, Oct. 28, 2015 (GLOBE NEWSWIRE) -- A new pill created by a team of MIT-trained researchers provides fecal transplant therapy without requiring the traditional, more invasive stool delivery...
Stellar Biotechnologies Presents at Annual 2013 National Science Foundation Conference
May 28, 2013 09:00 ET
|
Stellar Biotechnologies
PORT HUENEME, CA--(Marketwired - May 28, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of a poster at...
Stellar Biotechnologies Announces Publication of "Expert Review" Article on Clostridium Difficile Vaccines
April 30, 2013 09:00 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwired - Apr 30, 2013) - Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the world leader in sustainable manufacture of Keyhole...
Stellar Biotechnologies Announces Exclusive Option to License Clostridium Difficile Technology
April 10, 2012 09:05 ET
|
Stellar Biotechnologies, Inc.
PORT HUENEME, CA--(Marketwire - Apr 10, 2012) - Stellar Biotechnologies, Inc. ("Stellar") (TSX VENTURE: KLH) (PINKSHEETS: SBOTF) (FRANKFURT: RBT) today announced that it has entered into an...